# RAdvance

Clinical Policy Title:	clascoterone
Policy Number:	RxA.798
Drug(s) Applied:	Winlevi®
Original Policy Date:	04/13/2023
Last Review Date:	01/01/2024
Line of Business Policy Applies to:	All lines of business (except Medicare)

## Criteria

### I. Initial Approval Criteria

#### A. Acne Vulgaris (must meet all):

- 1. Diagnosis of acne vulgaris;
- Trial and failure of ≥ 2 of the following topical preparations, each from different medication classes, each used for ≥ 2 months, unless clinically significant adverse effects are experienced or all are contraindicated:
  - a. Topical antibiotics: clindamycin, erythromycin;
  - b. Topical anti-infectives: benzoyl peroxide;
  - c. Topical retinoids: tretinoin, tazarotene, adapalene;

# Approval Duration

All Lines of Business (except Medicare): 12 months

#### II. Continued Therapy Approval

A. Acne Vulgaris (must meet all):
 1. Member is currently receiving medication, excluding manufacturer samples;
 Approval Duration
 All Lines of Business (except Medicare): 12 months

#### References

 Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016;74:945-73. Available at: <u>https://pubmed.ncbi.nlm.nih.gov/26897386/</u>. Accessed December 18, 2023.

Review/Revision History	Review/Revision Date	P&T Approval Date
Policy established.	04/06/2023	04/13/2023
<ol> <li>Policy was reviewed:</li> <li>Removed prior age criteria.</li> <li>Removed prior dosing criteria.</li> <li>Updated approval duration.</li> <li>Removed reauthorization requirement for positive response to therapy.</li> <li>References were reviewed and updated.</li> </ol>	12/18/2023	01/012024

This clinical policy has been developed to authorize, modify, or determine coverage for individuals with similar conditions. Specific care and treatment may vary depending on individual need and benefits covered by the plan. This policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. This document may contain prescription brand name drugs that are trademarks of pharmaceutical manufacturers that are not affiliated with RxAdvance.

© 2024 RxAdvance Corporation. All rights reserved. This policy contains the confidential and proprietary information of RxAdvance. Unauthorized reproduction, distribution, modification, display, storage, transmission, or use of this policy or any information contained herein is strictly prohibited.